This disclosure pertains to devices and methods for administering one or more active ingredients, e.g., cannabinoids, terpenes, etc. In particular, the devices and methods disclosed herein administer one or more cannabinoids in a mist for transmucosal and transdermal absorption. In one embodiment, the device contains compositions comprising purified active ingredients (e.g., cannabinoids, terpenes, etc.) and/or unique combinations thereof for delivery via a mist for transmucosal and transdermal adsorption. In one embodiment, the device contains two separate compositions in separate chambers, wherein each composition comprises one or more of the active ingredients. In one embodiment, a composition in one chamber comprises a purified cannabinoid and the composition in the other chamber comprises a purified terpene. In an embodiment, the device operates without heating the active ingredients.

The instant disclosure provides methods and compositions for the treatment of skin disorders associated with itch, irritation, inflammation, and pain, such as psoriasis, eczema, and skin ulcers. The instant disclosure also provides methods and compositions for the treatment of ocular conditions associated with itch, irritation, inflammation, and pain, such as ocular itch, conjunctivitis and eye infections. Generally, compositions include modulator of gamma-amino-butyric-acid (GABA) receptor, such as propofol. The concentration of the GABA modulator in the composition is typically sufficiently high so as to activate GABA receptors in nerve and immune cells of the skin, but sufficiently low so as to not result in any significant systemic exposure.

The instant disclosure provides methods and compositions for the treatment of skin disorders associated with itch, irritation, inflammation, and pain, such as psoriasis, eczema, and skin ulcers. The instant disclosure also provides methods and compositions for the treatment of ocular conditions associated with itch, irritation, inflammation, and pain, such as ocular itch, conjunctivitis and eye infections. Generally, compositions include modulator of gamma-amino-butyric-acid (GABA) receptor, such as propofol. The concentration of the GABA modulator in the composition is typically sufficiently high so as to activate GABA receptors in nerve and immune cells of the skin, but sufficiently low so as to not result in any significant systemic exposure.

A topical liniment composition that boost muscle relaxation, increase blood flow, and increase cutaneous delivery of herbal extract that contains polyphenols derived from red chili, black pepper, cinnamon, and turmeric includes a quantity of castor-mineral oil-camphor solution, a quantity of eucalyptus oil, a quantity of clove oil, a quantity of peppermint oil, a quantity of frankincense oil, a quantity of herbal extract concentrate solution, and a quantity of castor oil. Aforementioned ingredients are heterogeneously mixed with each other to formulate the topical liniment composition at standard temperature and pressure (STP). Additionally, a quantity of petroleum jelly and a quantity of beeswax can be heterogeneously mixed with the topical liniment composition to formulate the topical balm composition.

A topical liniment composition that boost muscle relaxation, increase blood flow, and increase cutaneous delivery of herbal extract that contains polyphenols derived from red chili, black pepper, cinnamon, and turmeric includes a quantity of castor-mineral oil-camphor solution, a quantity of eucalyptus oil, a quantity of clove oil, a quantity of peppermint oil, a quantity of frankincense oil, a quantity of herbal extract concentrate solution, and a quantity of castor oil. Aforementioned ingredients are heterogeneously mixed with each other to formulate the topical liniment composition at standard temperature and pressure (STP). Additionally, a quantity of petroleum jelly and a quantity of beeswax can be heterogeneously mixed with the topical liniment composition to formulate the topical balm composition.

Described herein are compositions for topical use comprising active agents to provide pain relief. The compositions comprise a magnesium salt, a cannabinoid and at least one additional topical analgesic agent. Additionally described herein are methods for treating pain comprising administering to a person in need thereof a composition comprising a pharmaceutically effective amount of a cannabinoid, a magnesium salt and at least one of: methyl salicylate, and menthol.

Described herein are compositions for topical use comprising active agents to provide pain relief. The compositions comprise a magnesium salt, a cannabinoid and at least one additional topical analgesic agent. Additionally described herein are methods for treating pain comprising administering to a person in need thereof a composition comprising a pharmaceutically effective amount of a cannabinoid, a magnesium salt and at least one of: methyl salicylate, and menthol.

Described herein are compositions for topical use comprising active agents to provide pain relief. The compositions comprise a magnesium salt, a cannabinoid and at least one additional topical analgesic agent. Additionally described herein are methods for treating pain comprising administering to a person in need thereof a composition comprising a pharmaceutically effective amount of a cannabinoid, a magnesium salt and at least one of: methyl salicylate, and menthol.

Provided are methods for treating conditions and/or symptoms selected from the group consisting of ulcer, viral infection, bacterial infection, fungal infection, infectious disease, and inflammation comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising at least one cannabinoid in a specific amount; at least one terpene in a specific amount, and at least 5% by weight of a non-cannabinoid, non-terpene carrier, wherein said non-cannabinoid, non-terpene carrier comprises cellulose and a weight/weight ratio of a total amount of terpenes to a total amount of cannabinoids in said composition is from about 0.1:1 to about 1:1, or wherein said non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and a weight/weight ratio of a total amount of terpenes to a total amount cannabinoids in said composition is about 0.05:1 to about 1:1.

Provided are methods for treating conditions and/or symptoms selected from the group consisting of ulcer, viral infection, bacterial infection, fungal infection, infectious disease, and inflammation comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising at least one cannabinoid in a specific amount; at least one terpene in a specific amount, and at least 5% by weight of a non-cannabinoid, non-terpene carrier, wherein said non-cannabinoid, non-terpene carrier comprises cellulose and a weight/weight ratio of a total amount of terpenes to a total amount of cannabinoids in said composition is from about 0.1:1 to about 1:1, or wherein said non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and a weight/weight ratio of a total amount of terpenes to a total amount cannabinoids in said composition is about 0.05:1 to about 1:1.